


ADC

CMC

GLP

2023



Overview of the natural function of antibodies^[1]

B


10

Production route of hybridoma technology^[2]

VHH

VHH

ELISA



Nanobody production scheme using a phage display library^[3]

B


B

B



lg


9 9

B




B







Nectin-4 (4-1) Sorting Single B Cell




Nectin-4 (4-6) Sorting Single B Cell




Raji cells were mixed with human PBMCs, and different doses of Rituximab was added to induce ADCC, the killing of raji cells were detected through FACS(CFSE labeling of raji).



Raji cells were mixed with human AB serum, and different doses of Rituximab was added to induce CDC, the killing of raji cells were detected through FACS(PI staining of raji).




B cells were treated with Telitacept and induced with Baff for 72 hours, H3-thymidine incorporation were analyzed through scintillation counting.



T cells were treated with compound A and induced with ICOSL for 72 hours, H3-thymidine incorporation were analyzed through scintillation counting.



- A/IgG1 CD3/LPS PBMC 25
Luminex
- ICH IL-6 IL-10 3 MSD
IL-2 PBMC ELISA Luminex CBA
OKT3



LQ036

20222

LQ036

() IND

CDE

LQ036

LQ036

LQ036

NMPA


TGA

AAALACGLP-like

AAALACGLP-like

- /
-

:



- Animals:**
Female NOG mice
- Tumor Cells:**
Tumor mixed hPBMC (1:1) with 50% Matrigel, SC
- PBMC:**
injected before tumor cells inoculation
- Treatment:**
Bispecific antibody

Mean Tumor Volum (mm³) Day 14			
Group	TV	%TGI _{TV}	P Value
Vehicle	1639.53	/	/
Antibody	340.90	90.38	<0.001

/


PK



YYB-101

10 mg/kg

T_{max}



Toxicokinetic parameters on days 1 and 22 following intravenous infusion of YYB-101 at 10, 50, or 200 mg/kg perday in cynomolgus monkeys^[4]



2021 9 BAT6021 BAT6005 BAT6021 BAT6005
TIGIT BAT6021 BAT6005



2021 10 PD-L1/CD47 BAT7104 BAT7104
PD-L1/CD47 PD-1/PD-L1 BAT7104
GLP BAT7104



2022 5 IgE JYB1904 JYB1904 IgE
JYB1904
GLP JYB1904



2022 6 CD19/CD3/CD28 CC312 IND FDA
CD28 CC312
CC312 GLP



2022 10 (GT90008) GT90008 PD-L1
GT90008 /
GLP



2022 10 HCW Biologics Inc. HCW9218 FDA HCW9218
II IL-15/IL-15 NK CD8⁺ T
HCW9218 HCW GLP
SEND HCW9218 FDA



2023 7 NB002 FDA NB002 TIM-3
T NK NB002
DC TIM-3
NB002 IND
FDA

:

- [1] Ivana Spasevska. An outlook on bispecific antibodies: Methods of production and therapeutic benefits.
- [2] Abdullah F U H Saeed, et al. Antibody Engineering for Pursuing a Healthier Future. Front Microbiol. 2017 Mar 28;8:495. doi: 10.3389/fmicb.2017.00495.
- [3] MA Lin-lin, et al. Construction and screening of phage display library for TIM-3 nanobody. Acta Pharmaceutica Sinica 2018, 53 (3): 388-395.
- [4] Hyori Kim, et al. Preclinical development of a humanized neutralizing antibody targeting HGF. Exp Mol Med. 2017 Mar 24;49(3):e309. doi: 10.1038/emm.2017.21.



marketing@medicilon.com
50 Soldiers Field Place, Boston, MA 02135
www.medicilon.com +1(626)986-9880